- Press Release -

A recently revamped Fact.MR report projects that the global cardiac ablation technologies market is likely to reach US$ 15,007.95 Mn by 2032, registering a staggering 11.8% CAGR across the 2022-2032 forecast period. Increased surgical procedures for treating atrial fibrillation is primarily steering demand for cardiac ablation technologies.

From 2017 to 2021, sales of cardiac ablation technology devices experienced an incline of 11.1% in value CAGR terms. The market closed in at a valuation of US$ 4,427.89 Mn by the end of the aforementioned historical period. Prospects remained largely unaltered during the height of the COVID-19 pandemic, given the adverse effect of the disease on the circulatory system.

According to the Centres for Disease Control and Prevention (CDC), an estimated population between 2.7 million and 6.1 million people in the U.S. are said to be affected by atrial fibrillation. It further highlights that 166,793 death certificates in the U.S mentioned atrial fibrillation and 26,077 of these deaths occurred with atrial fibrillation as the underlying cause of death. These statistics shed light on the growing prevalence of atrial fibrillation and hint a good growth turnover for the cardiac ablation technology market.

Key Takeaways from the Market Study

• Global cardiac ablation technologies market to reach US$ 4,919.35 Mn by 2022
• By technology type, radiofrequency cardiac ablation to accumulate over 50% revenue
• Atrial fibrillation to remain primary cardiac ablation technologies application area
• North America to account for 37% of global cardiac ablation technologies revenue
• Asia Pacific to be highly opportunistic a market, capturing 40% of global revenue

“Rising prevalence of cardiac ailments amid prevalence of sedentary lifestyles is prompting patients to opt for multiple surgical treatments, expanding the scope for cardiac ablation technologies,” comments a Fact.MR analyst.

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advancements, mergers, and acquisitions.

• In 2018, the Johnson & Johnson Company announced the launch of the CARTO VIZIGO bi-directional guiding sheath in the U.S. market. This product helps electrophysiologists reduce their dependency on fluoroscopy.
• In October 2021, Boston Scientific entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access.

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the cardiac ablation technologies market, presenting historical demand data (2017-2021) and forecast statistics from 2022 to 2032.

The study divulges essential insights on the market based on technology type (radiofrequency, ultrasound, cryoablation, microwave, laser and others) and application (atrial fibrillation, ventricular tachycardia and others) across five major regions (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).

About the Healthcare Division at Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned Cardiac ablation technologies team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare market across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

For more information, refer to our market research report or contact the PR author.

Shambhu Nath Jha

Fact.MR

Sr. Consultant - Healthcare

E-mail: shambhu@factmr.com